Qatar v. Ecuador to kick off FIFA World Cup 2022™ on 20 NovemberRead more Webb Fontaine Announces Launch of Niger National Single Window (NNSW) to Bolster TradeRead more Ethiopia: Loan from United Nations Fund Allows Food and Agriculture Organization (FAO) to Scale Up Fertilizers for Farmers in TigrayRead more How Choosing the Right Printer Helps Small Businesses and Content Creators to Save Time, Maximise Productivity and Achieve GrowthRead more The United States Contributes USD $223 Million to Help World Food Programme (WFP) Save Lives and Stave Off Severe Hunger in South SudanRead more Eritrea: World Breastfeeding WeekRead more Eritrean community festival in Scandinavian countriesRead more IOM: Uptick in Migrants Heading Home as World Rebounds from COVID-19Read more Network International & Infobip to offer WhatsApp for Business Banking Services to Financial Institution Clients across AfricaRead more Ambassador Jacobson Visits Gondar in the Amhara Region to Show Continued U.S. Support for the Humanitarian and Development Needs of EthiopiansRead more

BioNTech: COVID-19 vaccine tests show progress

show caption
Juancho Torres
Print Friendly and PDF

Jul 21, 2020 - 09:45 AM

ANKARA (AA) – German-based biotech firm BioNTech announced on Monday that it had observed progress in ongoing research with US drug giant Pfizer to develop a vaccine against the novel coronavirus.

Preliminary results were released by the companies and are under scientific peer-review for publication.

According to the early data, the vaccine generated antibodies, as well as T-cell responses, at “remarkably low dose levels.”

“It is encouraging that the data on BNT162b1 [vaccine candidate] from the German study cohort are very much in line with what we have seen in the U.S. study cohort,” said Dr. Ozlem Tureci, co-founder of BioNTech, in the statement, adding that the generation of antibodies and T-cell responses would be important to receive clearance for a potential vaccine.

“These interim results from the German study, combined with initial data from the U.S. study, highlight the potential of this mRNA-based vaccine approach and represent an important step forward in our development efforts for the BNT162 program,” said Kathrin U. Jansen, head of vaccine research and development at Pfizer.

The companies announced on July 1 that the vaccine generated antibodies stronger than the average recovered COVID-19 patient in its US trial.

The next step will be for the firms to determine a dose level and select among multiple vaccine candidates, before progressing to a global safety and efficacy trial that could involve up to 30,000 healthy participants. This larger trial is anticipated to begin in late July 2020 “if regulatory approval is received.”

Since originating in China last December, the pandemic has claimed nearly 607,000 lives in 188 countries and regions.

Over 14.5 million cases have been reported worldwide, while recoveries have exceeded 8.1 million so far, according to figures compiled by the US’ Johns Hopkins University. (Busra Nur Bilgic Cakmak)


ZONNTECH.COM uses both Facebook and Disqus comment systems to make it easier for you to contribute. We encourage all readers to share their views on our articles and blog posts. All comments should be relevant to the topic. By posting, you agree to our Privacy Policy. We are committed to maintaining a lively but civil forum for discussion, so we ask you to avoid personal attacks, name-calling, foul language or other inappropriate behavior. Please keep your comments relevant and respectful. By leaving the ‘Post to Facebook’ box selected – when using Facebook comment system – your comment will be published to your Facebook profile in addition to the space below. If you encounter a comment that is abusive, click the “X” in the upper right corner of the Facebook comment box to report spam or abuse. You can also email us.